http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110804594-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2312 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078 |
filingDate | 2019-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-110804594-B |
titleOfInvention | Engineered antigen presenting cells and their use for activating CD3+ immune cells |
abstract | The invention discloses an engineered antigen presenting cell and application thereof in activating CD3+ immune cells. The engineered antigen presenting cell is obtained by introducing exogenous genes into a wild-type antigen presenting cell through an engineering means so as to over-express recombinant interleukin-12 and soluble CD 80. The invention promotes the activation of CD3+ immune cells through the combined synergistic effect of recombinant interleukin-12 and soluble CD 80. |
priorityDate | 2019-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 787.